Today, nearly all patients with septic shock receive the same first-line therapy. However, early research suggests that some ...
Treatments that target the renin-angiotensin-aldosterone system (RAAS) don’t improve outcomes in adult patients hospitalized with acute COVID-19. Three separate trials of different RAAS-related ...
A recent study posted to the medRxiv* preprint server investigated the association of renin-angiotensin-aldosterone system (RAAS)-mediated hypertension (HT) with coronavirus disease 2019 (COVID-19).
Role of the RAAS in the Pathophysiology of Heart Failure ACE inhibitors have no effect on angiotensin II formed by alternate pathways. In contrast, ARBs would be expected to inhibit the biologic ...
At one time, dual RAAS blockade was expected to provide more-complete inhibition of RAAS among patients with DKD. Results of large clinical trials dashed these hopes, finding increased risk of AKI and ...
What if there were a straightforward and relatively inexpensive way to lower the incidence of heart failure (HF), renal disease, stroke, and cognitive impairment? Cardiologist Bertram Pitt, MD, said ...
A meta-analysis revealed that RAAS inhibitor monotherapy in patients with primary FSGS is significantly associated with a 32% reduction in proteinuria. Renin-angiotensin-aldosterone system (RAAS) ...
A sick child taking medication Real-world data on use of RAAS inhibitors can be used to support future pragmatic studies to optimize management of childhood-onset SLE, according to investigators.
Severe COVID-19 arises in part from the SARS-CoV-2 virus’s impact on mitochondria, tiny oxygen-burning power plants in cells, which can help trigger a cascade of organ- and immune system-damaging ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results